Lucira Health is Soaring Monday: Here Are The Details
Lucira Health Inc (NASDAQ: LHDX) shares are soaring on Monday after the company announced U.S.
Lucy Scientific Discovery Announces First Commercial Sale Of Psilocybin Following Initial Delivery Of DMT And 5-MeO-DMT To Hadassah BrainLabs
Lucy Scientific Discovery Inc. ("Lucy" or the "Company") (NASDAQ:LSDI), an early-stage manufacturing company that is focused on becoming the premier research, development, and manufacturing
SciSparc Signs Agreement For The Supply Of CBD-Rich Cannabis Oil For Its Clinical Trial On Children With Autism Spectrum Disorder
The cannabis oil will be used as a part of the Company's proprietary SCI-210 treatment combination of CBD and CannAmide™
Rhythm Pharmaceuticals Acquires Xinvento, A Netherlands-based Biotech Company Focused On Developing Therapies For Congenital Hyperinsulinism For $5M Upfront
According to the terms of the acquisition agreement, Rhythm B.V. will purchase 100 percent of Xinvento’s fully-diluted equity for an upfront payment of $5 million (subject to customary adjustments) with an
Pfizer In Early Talks To Buy Cancer-Focused Seagen: WSJ
Pfizer Inc (NYSE:PFE) is in early discussions to purchase biotechnology company Seagen Inc (NASDAQ:SGEN), The Wall Street Journal reported late on…
FDA Authorizes Lucira’s Over-the-Counter At-Home Test To Detect Both Influenza, COVID-19 Viruses
https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-over-counter-home-test-detect-both-influenza-and-covid-19-viruses
BioRxiv Journal Article Out On Jaguar Health’s Drug Titled “Effects Of Orally Administered Crofelemer On The Incidence And Severity Of Neratinib-Induced Diarrhea In Female Dogs”
https://www.biorxiv.org/content/10.1101/2023.02.23.529666v1
FDA Slams Break On Fulcrum Therapeutics’ Sickle Cell Disease Study, Shares Plummet
The FDA verbally informed Fulcrum Therapeutics Inc (NASDAQ:FULC) that it has issued a full clinical hold regarding the Investigational New Drug (IND)…
Novartis Takes Down $80M NASH Pact With Pliant Therapeutics
Novartis AG (NYSE:NVS) has decided to terminate the Collaboration and License Agreement with Pliant Therapeutics, Inc.(NASDAQ:PLRX), announced in 2019. Novartis told…
‘New Phase 3 Data Presented At WORLDSymposium Reinforce Nexviazyme As Potential New Standard Of Care For All People Living With Late-Onset Pompe Disease’
New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with